

MDS Quarterly e-Newsletter 3 – References

Assessing the Elderly MDS Patient for Comorbidities, Frailty and Treatment Fitness

References

1. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. *J Natl Cancer Inst.* 2008;100(21):1542-1551.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood.* 1997;89:2079-2088.
3. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. *Blood.* 2012;119:159-166.
4. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood.* 2009;114(5):937-951.
5. Della Porta MG, Malcovati L. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. *Haematologica.* 2009;94:602-606.
6. Naqvi K, Garcia-Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. *J Clin Oncol.* 2011;29:2240-2246.
7. Sperr WR, Wimazal F, Kundi M, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. *Ann Oncol.* 2010;21:114-119.
8. Wang R, Gross CP, Halene S, Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. *Leuk Res.* 2009;33:1594-1598.
9. Zipperer E, Palz D, Nachtkamp K, et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. *Haematologica.* 2009;94:729-732.
10. Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. *Haematologica.* 2011 Mar;96(3):441-449.
11. NCCN Guidelines Version 1.2016. Myelodysplastic Syndromes. MS-16.
12. Adult Comorbidity Evaluation.
<https://www.rtog.org/LinkClick.aspx?fileticket=xMGEfaLHRuM%3D&tabid=290>. Accessed 3/2/16.
13. Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. *Haematologica.* 2011;96(3):441-449.
14. Malcovati L, Della Porta M, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria. A basis for clinical decision-making. *J Clin Oncol.* 2005;23:7594-7603.
15. Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. *J Clin Oncol.* 2008;26(2):3607-3613.
16. Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. *Blood.* 2008;111(2):574-582.

17. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. *Blood*. 2007;110(13):4606-4613.
18. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. *Blood*. 2004;104(2):579-585.
19. Alessandrino EP, Della Porta MG, Bacigalupo A, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo. *Blood*. 2008;112(3):895-902.
20. Dayer N, Naqvi K, Jabbour E, et al. Impact of comorbidities by ACE-27 in the revised IPSS for patients with myelodysplastic syndromes. *Am J Hematol*. 2014;89(5):509-516.
21. Versteeg KS, Konings IR, Lagaay AM, et al. Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review. *Ann Oncol*. 2014;25:1914-1918.
22. Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy—a systematic review. *Leuk Res*. 2014;38(3):275-283.
23. NCCN Clinical Practice Guidelines. Older Adult Oncology. Version 1.2016.
24. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. *J Clin Oncol*. 2007;25(14):1824-1831.
25. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. *CMAJ*. 2005;173(5):489-495.
26. Stauder R. The challenge of individualized risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes patients. *Ann Hematol*. 2012;91(9):1333-1343.
27. Atalla E, Horowitz MM, Logan B, et al. Outcome of patients 65 years and older with myelodysplastic syndrome receiving allogeneic hematopoietic stem cell transplantation compared to patients 55-64 years of age. 2015 ASH Annual Meeting. Presented December 6, 2015.